Literature DB >> 10953178

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

C R Jack1, R C Petersen, Y Xu, P C O'Brien, G E Smith, R J Ivnik, B F Boeve, E G Tangalos, E Kokmen.   

Abstract

BACKGROUND: The cognitive continuum in the elderly population can be conceptually divided into those who are functioning normally (control subjects), those with a mild cognitive impairment (MCI), and those with probable AD.
OBJECTIVES: To test the hypothesis that the annualized rates of hippocampal atrophy differ as a function of both baseline and change in clinical group membership (control, MCI, or AD).
METHODS: The authors identified 129 subjects from the Mayo Clinic AD Research Center/AD Patient Registry who met established criteria for normal control subjects, MCI, or probable AD, both at entry and at the time of a subsequent clinical follow-up evaluation 3 +/- 1 years later. Each subject underwent an MRI examination of the head at the time of the initial assessment and at follow-up clinical assessment; the annualized percentage change in hippocampal volume was computed. Subjects who were classified as controls or patients with MCI at baseline could either remain cognitively stable or could decline to a lower functioning group over the period of observation.
RESULTS: The annualized rates of hippocampal volume loss for each of the three initial clinical groups decreased progressively in the following order: AD > MC > control. Within the control and MCI groups, those who declined had a significantly greater rate of volume loss than those who remained clinically stable. The mean annualized rates of hippocampal atrophy by follow-up clinical group were: control-stable 1.73%, control-decliner 2.81%, MCI-stable 2.55%, MCI-decliner 3.69%, AD 3. 5%.
CONCLUSION: Rates of hippocampal atrophy match both baseline cognitive status and the change in cognitive status over time in elderly persons who lie along the cognitive continuum from normal to MCI to AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953178      PMCID: PMC2724764          DOI: 10.1212/wnl.55.4.484

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Mayo Clinic Alzheimer's Disease Patient Registry.

Authors:  R C Petersen; E Kokmen; E Tangalos; R J Ivnik; L T Kurland
Journal:  Aging (Milano)       Date:  1990-12

Review 4.  MRI-based hippocampal volume measurements in epilepsy.

Authors:  C R Jack
Journal:  Epilepsia       Date:  1994       Impact factor: 5.864

5.  Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease.

Authors:  K A Jobst; A D Smith; M Szatmari; M M Esiri; A Jaskowski; N Hindley; B McDonald; A J Molyneux
Journal:  Lancet       Date:  1994-04-02       Impact factor: 79.321

6.  Mild cognitive impairment in the elderly: predictors of dementia.

Authors:  C Flicker; S H Ferris; B Reisberg
Journal:  Neurology       Date:  1991-07       Impact factor: 9.910

7.  Senile dementia and healthy aging: a longitudinal CT study.

Authors:  F J Wippold; M H Gado; J C Morris; J M Duchek; E A Grant
Journal:  Radiology       Date:  1991-04       Impact factor: 11.105

Review 8.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease.

Authors:  C R Jack; R C Petersen; P C O'Brien; E G Tangalos
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

10.  Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults.

Authors:  C R Jack; C K Twomey; A R Zinsmeister; F W Sharbrough; R C Petersen; G D Cascino
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

View more
  292 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Past glory and future promise: maximizing and improving understanding of atrophy patterns in the diagnosis of degenerative dementias.

Authors:  Bruce L Miller
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

3.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Authors:  Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

4.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

Review 5.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

6.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

Authors:  C R Jack; M Slomkowski; S Gracon; T M Hoover; J P Felmlee; K Stewart; Y Xu; M Shiung; P C O'Brien; R Cha; D Knopman; R C Petersen
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

7.  [Functional magnetic resonance imaging and dementia].

Authors:  F L Giesel; A Hempel; P Schönknecht; T Wüstenberg; M A Weber; J Schröder; M Essig
Journal:  Radiologe       Date:  2003-06-24       Impact factor: 0.635

Review 8.  Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Stephanie L Leal; Michael A Yassa
Journal:  Ageing Res Rev       Date:  2013-02-04       Impact factor: 10.895

Review 9.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

10.  Lower hippocampal volume predicts decrements in lane control among drivers with amnestic mild cognitive impairment.

Authors:  H Randall Griffith; Ozioma C Okonkwo; Christopher C Stewart; Luke E Stoeckel; Jan A den Hollander; Jennifer M Elgin; Lindy E Harrell; John C Brockington; David G Clark; Karlene K Ball; Cynthia Owsley; Daniel C Marson; Virginia G Wadley
Journal:  J Geriatr Psychiatry Neurol       Date:  2013-12       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.